RxDoctor Payments Data

Abhishek Gulati, MD

Internal Medicine · Fresno, CANPI 1629380308

Payments from drug & device makers

$16,950in general payments, 2019–2025

Across 345 payments — averaging $49.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Steris Corporation$5K
  • US Endoscopy$4K
  • Boston Scientific$2K
  • AbbVie$2K
  • Apollo Endosurgery US Inc$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$600
  • plus $2K from 29 others

What the payments were for

  • Consulting fees$4,02024%
  • Travel & lodging$5,61533%
  • Food & beverage$7,28143%
  • Education$340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,950 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$208,602
Medicare patients
628
Services billed
1,557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide12$15,764
MotegrityPrucalopride Succinate11$7,145
Pantoprazole Sodium359$5,817
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl254$3,716
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl91$1,350
Sucralfate15$1,118
Famotidine58$638
Lactulose17$366
Omeprazole21$317
ConstuloseLactulose11$304
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl14$230
Dicyclomine Hcl15$130
Ciprofloxacin Hcl14$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,657$15,76412 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$208$7,14511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →